EGFR Non-Small Cell Lung Cancer Market · GlobeNewswire Inc. The report offers comprehensive insights including market size, ...
Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight The non-small cell lung cancer clinical trial analysis report ...
Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Applicatio ...
MedPage Today on MSN
High Rate of Surgical Success in Complex NSCLC With Neoadjuvant Chemoimmunotherapy
Three-fourths of patients had cancer-free mediastinal lymph nodes, clear surgical margins ...
New findings of an Alliance Foundation Trials study show combining immunotherapy and chemotherapy before surgery improves ...
A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) ...
Of particular interest were novel therapies for EGFR exon 20 insertion mutations in non-small cell lung cancer, which ...
An AI model applied to pathology slides accurately predicts immunotherapy response in patients with metastatic non-small cell ...
Dr. Deborah Doroshow presents Sandra, a 54-year-old never-smoker diagnosed 14 months ago with stage IVA non-small cell lung ...
Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib led to clinical benefit in patients with ...
The FDA has accepted the NDA for zipalertinib to treat adult patients with locally advanced or metastatic EGFR exon 20 insertion-mutated NSCLC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results